1015073-43-4

Basic information

• Product Name: PSI 7411
• Synonyms: PSI 7411
• CAS NO: 1015073-43-4
• Molecular Weight: 0
• Mol File: 1015073-43-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: PSI 7411(CAS DataBase Reference)
• NIST Chemistry Reference: PSI 7411(1015073-43-4)
• EPA Substance Registry System: PSI 7411(1015073-43-4)

Safety Data

• Hazardous Substances Data: 1015073-43-4(Hazardous Substances Data)

Usage

General Description

"PSI 7411" is a type of lithium-ion battery electrolyte additive that is often used to enhance the performance and safety of lithium-ion batteries. It is composed of a mixture of solvents, salts, and additives, which work together to improve the thermal stability, cycling performance, and safety of the battery. This additive is designed to help increase the operational range and lifespan of lithium-ion batteries, making it a crucial component for electronic devices and electric vehicles. Additionally, "PSI 7411" has been shown to decrease the risk of thermal runaway and improve the overall energy density of lithium-ion batteries, making it a valuable chemical for the advancement of battery technology.

Upstream product

• 863329-66-2 2'-deoxy-2'-fluoro-2'-methyluridine 

Downstream Products

• 1015073-42-3 GS-461203 

Relevant articles and documents

Synthesis and Anti-HCV Activities of 4′-Fluoro-2′-Substituted Uridine Triphosphates and Nucleotide Prodrugs: Discovery of 4′-Fluoro-2′- C-methyluridine 5′-Phosphoramidate Prodrug (AL-335) for the Treatment of Hepatitis C Infection

We report the synthesis and biological evaluation of a series of 4′-fluoro-2′-C-substituted uridines. Triphosphates of the uridine analogues exhibited a potent inhibition of hepatitis C virus (HCV) NS5B polymerase with IC50 values as low as 27 nM. In an HCV subgenomic replicon assay, the phosphoramidate prodrugs of these uridine analogues demonstrated a very potent activity with EC50 values as low as 20 nM. A lead compound AL-335 (53) demonstrated high levels of the nucleoside triphosphate in vitro in primary human hepatocytes and Huh-7 cells as well as in dog liver following a single oral dose. Compound 53 was selected for the clinical development where it showed promising results in phase 1 and 2 trials.